Chemerin as a Driver of Hypertension: A Consideration

David J. Ferland,1 Adam E. Mullick,2 and Stephanie W. Watts1

The protein chemerin (tazarotene-induced gene, TIG2; RARRES2) is a relatively new adipokine. Many studies support that circulating chemerin levels associate strongly and positively with body mass index, visceral fat, and blood pressure. Here, we focus on the specific relationship of chemerin and blood pressure with the goal of understanding whether and how chemerin drives (pathological) changes in blood pressure such that it could be interfered with therapeutically. We dissect the biosynthesis of chemerin and how current antihypertensive medications change chemerin metabolism. This is followed with a review of what is known about where chemerin is synthesized in the body and what chemerin and its receptors can do to the physiological function of organs important to blood pressure determination (e.g., brain, heart, kidneys, blood vessels, adrenal, and sympathetic nervous system). We synthesize from the literature our best understanding of the mechanisms by which chemerin modifies blood pressure, with knowledge that plasma/serum levels of chemerin may be limited in their pathological relevance. This review reveals several gaps in our knowledge of chemerin biology that could be filled by the collective work of protein chemists, biologists, pharmacologists, and clinicians.

Keywords: blood pressure; chemerin; hypertension; obesity

doi:10.1093/ajh/hpaa084

CHEMERIN BIOSYNTHESIS (SITES OF AND MECHANISM)

The earliest discoveries around chemerin were made in the immune system, classifying chemerin as a chemokine. Chemerin activates plasmacytoid dendritic cells, natural killer cells, and tissue macrophages.1–7 In 2007, chemerin was identified as an adipokine and the receptor through which it was originally identified to work termed chemerin chemokine-like receptor 1 (CMKLR1) or ChemR23; this receptor is now named Chemerin1.8–13 Context matters relative to the role chemerin plays in biological functions. Prochemerin is made predominantly within the hepatocyte and adipocyte. Figure 1 compares qualitative comparisons of chemerin mRNA levels in some human tissues vs. those in the rat. This figure was drawn to understand whether the rodent (rat) might serve as a model for the human, and to give a quick view of relative organ expression. We do not include tissues involved with reproduction (e.g., ovary, testes, and placenta) or bone in this figure, nor have we included studies done in the mouse. While studies of chemerin mRNA in mouse tissues are more plentiful than those in the rat, we report data in the rat because of its importance as a model in cardiovascular studies. The liver was set to a maximum value with all other values compared with it, given that the absolute magnitude of chemerin mRNA is greatest in the liver of both species. The human levels are reported from the Human Atlas (https://www.proteinatlas.org/ENSG00000106538-RARRES2/tissue). The rat measures, less in number because of the size of the study, were done in the laboratory of one of the authors, Dr Adam Mullick. Where a measure is absent in this specific rat study, the bar is marked with not yet measured or a reference 14,15 is placed for a different study that validates the qualitative expression of mRNA in that specific rat tissue. Secreted prochemerin is cleaved at the N-terminus to form chemerin (ref. 16; Figure 2). This molecule (Chem 20–163 or a 143 amino acid peptide) is proteolytically degraded by a host of diverse enzymes that include carboxypeptidases, cathepsins, elastase, Factor XIIa, Factor XIa, chymase, plasmin, and trypsin, to name a few.7,16–25 Importantly, some of these enzymes are involved in the renin–angiotensin system and are targets of currently used antihypertensive medications. The intersection of therapeutics with chemerin processing and thus ultimate functioning in the body will be later discussed.

Chemerin isoforms are named such that number after chemerin refers to the length of the isoform relative to the original 163 amino acid peptide. These include chemerin 125, chemerin 152, chemerin 154, chemerin 155, chemerin 156, chemerin 157, chemerin 158, and chemerin 163 with chemerin 157 producing the most potent responses at Chemerin1. We will term these r/h isoforms to indicate

Correspondence: Stephanie W. Watts (wattss@msu.edu).

Initially submitted March 16, 2020; date of first revision May 6, 2020; accepted for publication May 20, 2020; online publication May 26, 2020.

© The Author(s) 2020. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Isoforms of chemerin become an issue in determining whether chemerin measures from circulating blood or plasma are a useful biomarker because isoforms can have opposite biological effects, such as anti-inflammatory actions. Chemerin isoforms have not been stratified to different magnitudes of blood pressure.

The role of chemerin in hypertension is complicated by the possibility that chemerin processing may be directly impacted by antihypertensive drugs. For example, angiotensin-converting enzyme degrades chemerin 20–163 to inactive chemerin 152 due to angiotensin-converting enzyme's action as a carboxypeptidase. Angiotensin-converting enzyme inhibition would thus be predicted to increase the concentration of more active chemerin isoforms. Similarly, chymase (also an angiotensin II producer) metabolizes chemerin to both active and inactive forms. The angiotensin-converting enzyme inhibitor fosinopril reduced the elevation of serum and renal chemerin in a streptozocin-induced diabetic nephropathy in the rat. Finally, the PPARgamma agonists rosiglitazone, pioglitazone, and the angiotensin receptor antagonist irbesartan reduced the elevation in chemerin protein and Chemerin1 receptor observed in the kidney of the streptozocin-induced diabetic rat. For these latter studies, it is simply unclear if chemerin levels were reduced because disease was being treated vs. chemerin processing being modified by these drugs.

CHEMERIN RECEPTORS AND TOOLS FOR CHEMERIN BIOLOGY

There are 3 receptors for chemerin—Chemerin1, Chemerin2, and C–C chemokine receptor like 2 (CCRL2). All receptors are members of the G-protein-coupled receptor family and are recognized by the International Union of Pharmacology (Figure 2; www.guidetopharmacology.org; target id = 78 for CCRL2; target id = 79 for chemerin receptor1; target id = 82 for chemerin receptor2). We repeat that chemerin receptors have had name changes in the last ten years. Chemerin1 was formerly known as ChemR23 or CMKLR1, and Chemerin2 as G-protein-coupled receptor 1 (GPR1). Chemerin1 and Chemerin2 mediate the direct biological effects of chemerin (Figure 2). CCRL2 is described as a chaperone for chemerin. Chemerin isoforms produced endogenously serve as the cognate ligands for individual chemerin receptors (Figure 3). Resolvins also appear to be agonists (substances that stimulate receptor function) at Chemerin1. While antibodies are available for chemerin receptors, most of these antibodies have not been validated in experimental samples in which the chemerin receptor protein is knocked out/abolished.

Pharmacological tools to study chemerin receptor function are also available but are not numerous—this is a field in the process of development. The agonist chemerin-9 constitutes residues 149–157 of the full-length peptide, mimics r/h chemerin 157, and retains biological activity at both Chemerin1 and Chemerin2 receptors (www.guidetopharmacology.org). The Chemerin1 receptor antagonist CCX832 was developed by Chemocentryx and
validated within our laboratory (Figure 3). These 2 tools—chemerin-9 and CCX832—have been the most commonly used tools in experimental laboratories. Other tools are being developed. For example, Graham et al. developed 2-(α-naphthoyl)ethyltrimethylammonium iodide as a Chemerin1 antagonist; this molecule is recognized by IUPHAR as such. Chemerin2 antagonists are not known.

Our team was also involved in the development of a different type of pharmacological tool to reduce chemerin expression vs. mimicking or antagonizing its effects. Dr. Adam Mullick of Ionis Pharmaceuticals created a series of antisense oligonucleotides (ASOs) that facilitate degradation of chemerin pre-mRNA through RNase H1-dependent mechanisms (Figure 3). As such, this destroys the ability of the cell to make chemerin protein. Due to hepatic and extrahepatic expression of chemerin, robust inhibition of chemerin at all sites of its expression requires the most potent ASO design. This is achieved by using Generation (Gen) 2.5 ASOs that contain a bicyclic sugar, 2',4'-methylene bridged nucleic acid with a (S)-constrained ethyl modification (cEt). Importantly, RNase H1-active ASOs are designed as gapmers, as RNA cleavage is only supported at positions containing unmodified sugars. Thus, a typical Gen 2.5 design is a 16mer 3-10-3, with the 3 flanking nucleotides at the 5’ and 3’ ends containing cEt modified sugars and a gap of 10 nucleotides containing DNA. As with all ASOs, the nucleotides are connected via a phosphorothioate backbone which is important for nuclease resistance and pharmacokinetic properties necessary for tissue uptake. Lastly, the same Gen 2.5 ASO chemerin with addition of a 5’-Trishexylamino-(THA)-C2GalNAc5’ endcap (GalNAc) targets the ASO specifically to the liver. This is because of the high affinity of N-acetylgalactosamine (GalNAc) for the asialoglycoprotein receptor, which is highly expressed in hepatocytes. These tools allow us to begin to dissect contributions of chemerin to blood pressure regulation and will be discussed within this review.

**CHEMERIN’S MECHANISTIC INFLUENCE OVER BLOOD PRESSURE AND HYPERTENSION**

As evidenced by the evolution of chemerin’s classification from chemokine to adipokine, chemerin is involved in a wide variety of physiological processes. The cardiovascular system, especially as it relates to hypertension, is one such system in which chemerin has a multiplicity of effects. While there is not yet a clear understanding of how chemerin participates in human hypertension, we can begin to piece this puzzle together by understanding its individual parts. Below, we address each of the systems/organs well-established to play a role in blood pressure (dys)regulation, and how chemerin modifies the function of these important elements of the cardiovascular system (Figure 4). Below, we offer an introduction
to chemerin function in cardiovascular organs. Because of reference limitations, we have not been able to exhaustively reference the number of papers for the totality of studies done in each organ. We apologize to our colleagues for this.

Our overall opinion at this time is that the mechanistic chemerin research has been deepest in the vascular system; this section of the review is the most thorough in its references and mechanistic discussion. This is in part because this is our expertise. This focus does not mean that vascular work on chemerin is yet sufficient, nor does it mean that no research has been done in other systems. We do not mean to dismiss any organ as being unimportant by citing fewer references. It is a goal of this review to highlight that there is significant important work yet to be done on chemerin in tissues of the cardiovascular system. This is a call to those far more expert than we in these areas to meet the challenge of mechanistic studies in these areas.

The blood vessel

The vasculature, both arteries and veins, contain an endothelium, smooth muscle layer, adventitia, and perivascular adipose tissue (PVAT). The first 3 listed layers are well established. PVAT is gaining ground to be recognized as a vessel tissue layer of its own. In regard to chemerin-stimulated vasoactivity, the aorta and mesenteric resistance vessels are the most studied at this time.

Chemerin, either as chemerin-9 or full-length recombinant peptide, causes constriction of isolated arteries (rat and human) and potentiates the effect of established vasoconstrictors such as endothelin-1. Importantly, chemerin-induced contraction is significantly enhanced when the endothelium is removed. Specific parts of the formally recognized blood vessel—the endothelial cell, the smooth muscle cell, and the sympathetic nerves that innervate these tissues—are next considered.

Endothelium. The presence of a healthy endothelium clearly influences chemerin physiology. In endothelial cells, chemerin increases reactive oxygen species and may lead to decreased nitric oxide production. Nitric oxide synthase inhibitors increased the magnitude of contraction caused by chemerin-9, suggesting that chemerin might interact with receptors within the endothelium to reduce contraction or play a role in chemerin disposition. However, the full ability of chemerin-9 to cause constriction was only revealed with the removal of the endothelium, an action that is greater than inhibition of nitric oxide synthase. Direct endothelium-dependent contraction and/or relaxation stimulated by chemerin or chemerin-9 has not been reported. If observed, such an action would occur in opposition to the ability of chemerin to increase reactive oxygen species in endothelial cells, typically considered an event that promotes constriction. Understanding how chemerin affects the endothelial cell is important given that endothelial cell dysfunction is a hallmark of cardiovascular diseases, including hypertension.

Smooth muscle. Chemerin1 is present on the smooth muscle cell, with the caveat that antibodies used in the assays...
that would determine this (immunohistochemistry, Western analyses) have not been validated in a Chemerin1 knockout. As stated above, chemerin-9 and recombinant chemerin cause direct arterial contraction. Chemerin inhibits cyclic adenosine monophosphate production and contraction stimulated by chemerin is inhibited by pertussis toxin, supporting the role of the G protein G in chemerin-stimulated signal transduction. G proteins are also activated by Chemerin1. Activation of these pathways supported by these G proteins is consistent with chemerin causing vascular contraction. Multiple groups agree that Chemerin2 (aka GPR1) is not involved in smooth muscle responses to chemerin. However, chemerin receptor signaling may be more complicated than previously appreciated. Recombinant r/h chemerin 157 and its analog chemerin-9 elicit selective signaling (also known as biased signaling or signaling by biased agonists). This means that different chemerin isoforms elicit different second messenger signaling through the same receptor, making these events appear to be conducted through different receptors. For example, chemerin-9 but not the recombinant, full-length chemerin elevates intracellular calcium in a manner antagonized by CCX 832. Finally, chemerin is a mitogen in vascular smooth muscle cells and, when infused in the mouse, elevates blood pressure. This proliferative effect could influence the long-term remodeling of blood vessels in hypertension.

**PVAT.** We consider PVAT as an independent layer of the vessel, given that it can be readily dissected from the adventitia. There is increasing support that PVAT plays a role in creating a healthy/unhealthy environment for the vessel. Both chemerin and Chemerin1 receptor can be found in PVAT of experimental rodents and human. In fat, chemerin plays a beneficial autocrine role in adipogenesis but this specific role has not been investigated in PVAT. If there is a PVAT-specific role to chemerin, it makes this layer of the blood vessel more relevant in blood pressure regulation due to the proximity of the site of chemerin synthesis and its receptor expression in vascular smooth muscle cell and nerve.

**Microvasculature.** Aside from the cell/layer-specific effects of chemerin on the microvasculature, chemerin...
promotes angiogenesis, which is more elevated in type 2 diabetes mellitus patients with microvasculature complications. Chemerin’s positive association with angiogenesis is typically viewed through the lens of carcinogenesis, an area with a greater literature.

The sympathetic nervous system

The cell type in PVAT is predominantly adipocytes, but other cells and tissue types are present. These include sympathetic nerves that may be found in the connective tissue space between the smooth muscle and adipocyte layers. Chemerin has at least 2 functions in the vascular sympathetic nerve. First, chemerin made in PVAT promotes electrical-field stimulation (EFS)-induced superior mesenteric arterial contraction (a way to test nerve-mediated contraction) through activation of Chemerin1 receptor. EFS-induced contraction was determined to be both nerve- and adrenergic receptor-dependent, suggesting EFS activates sympathetic nerves. Second, exogenous chemerin-9 potentiates EFS-induced arterial contraction. These experimental findings in the rat support that chemerin enhances sympathetic nerve function. This is important in considering the contributions chemerin may make to blood pressure regulation and the multiple levels at which the sympathetic nervous system controls and regulates blood pressure.

The adrenal is part of the sympathetic nervous system and exerts short-term (medulla via epinephrine) and long-term (cortex via mineralocorticoids) control over blood pressure. Chemerin is found in both portions of the adrenal but Chemerin1 is only present in the cortex. Chemerin mRNA transcripts are found in the whole adrenal (at rather high levels in human) but it is not clear whether 1 or both divisions of the adrenal regulate chemerin-dependent blood pressure responses. The EFS experiments mentioned previously suggest that sympathetic nerve stimulation may lead to the release of chemerin. If chemerin is secreted in the adrenal medulla in response to sympathetic nerve activation, the receptors in the cortex could be activated. While the function of Chemerin1 in the cortex is unknown, the cross-section of chemerin and mineralocorticoids on long-term control over blood pressure warrants further investigation.

It is less clear whether the central nervous system uses chemerin and its receptors to regulate blood pressure, either in the short or long term. Studies in this area investigate the role of chemerin in central control of appetite/feeding behavior. Pig, cow, rat, and human brain contain mRNA and protein for chemerin as well as the Chemerin1 and Chemerin2 receptors. It is not known whether chemerin (including any of its metabolites) made from the periphery can cross the blood brain barrier, but 1 study suggests it might. Chemerin was given intraperitoneally to the rat, and decreased food intake and body weight compared with vehicle control, an event thought of as being centrally dependent. This particular area is ripe for mechanistic studies given the important control the central nervous system possesses over blood pressure and feeding.

The heart

Knowledge of chemerin expression, chemerin receptors and chemerin function in the heart is sparse. Chemerin mRNA is expressed in the heart of the rat, in which chemerin is a negative inotrope and may induce cellular insulin resistance. Chemerin, stimulated by tumor necrosis factor alpha, induced apoptosis in mouse cardiomyocytes. Chemerin processing is potentially regulated by peptidase inhibitor 16, a protein upregulated in cardiac disease. Specifically, upregulated peptidase inhibitor 16 inhibited chemerin activation in cardiomyocytes. While basic research on the effects of chemerin in the heart are sparse compared with that of the vasculature, epidemiological evidence supporting chemerin’s role in cardiac disease, many times associated with hypertension, has grown. Specifically, there is a positive correlation between chemerin protein serum/plasma concentration and various pathologies associated with the heart. These include atherosclerosis, hypertension, and atrial fibrillation, along with the more general designation of cardiovascular disease. Heart failure is a disease in which serum chemerin concentration may be a novel prognostic indicator.

Study of chemerin in cardiac (dys)function is an important new avenue of research. It is unknown whether the association of chemerin levels with cardiac dysfunctions described above are because of direct effects of chemerin on the (human) heart or are the results of the long-term secondary insults of chemerin elsewhere in the body (adipose tissue health, immune cell infiltration, sympathetic nerve control, and elevated blood pressure).

The kidneys

As found in literature for the heart, there are plentiful data from humans suggesting chemerin serum/plasma concentration is positively correlated with renal disease. However, multiple groups support the idea that elevated levels of chemerin in patients with chronic kidney disease are not because of overproduction of chemerin (at least by adipose tissue) but due to poor renal elimination. Dialysis directly decreased plasma chemerin concentration, supporting this idea.

While multiple groups have shown that the Chemerin1 receptor was not expressed in the kidney, others support its presence in rat and pig. Moreover, chemerin mRNA has been measured in the rat kidney and pig kidney. In the rat, a renal-specific induction of chemerin expression is observed in a model of hypertensive nephropathy. Importantly, in this same model, circulating chemerin levels were not elevated in disease. These cited studies do not, however, describe what the function of chemerin within the kidney might be. This underscores an important point of this review: the local/paracrine actions of chemerin may be the most important to biological function.

The immune system

This subject has been covered by excellent reviews (ref. for example). The inflammatory/anti-inflammatory actions
of chemerin remain an important aspect of chemerin’s function, especially given that hypertension has been described as an inflammatory disease. Briefly, active chemerin can serve as a potent chemoattractant for natural killer cells, macrophages, and dendritic cells. Activation of each of these cell types can be linked to an increase in blood pressure. Because of chemerin’s chemotactic nature, plasma circulating chemerin is an important component to the immune axis of chemerin. However, there is mounting evidence that plasma chemerin is not directly associated with increases in blood pressure. Finally, forms of chemerin have been described as anti-inflammatory, an area not without controversy. These findings, coupled with the ability of chemerin to function in potentially biased means at its receptors, have further confused our understanding of chemerin in the inflammatory system.

CHEMERIN MEASURES IN NORMAL AND HUMANS WITH CARDIOVASCULAR DISEASE: WHAT DOES IT MEAN?

Since its discovery, dozens of studies have reported on measurements of circulating (serum or plasma) chemerin, with the idea that such a measure would serve as a potential biomarker for cardiovascular disease. Enzyme-linked immunosorbent assays have been the most used analytic assay. These assays have allowed the field to gain a sense of what is a level of circulating chemerin protein is in humans, both healthy and with disease. Figure 5 reports findings from over 2 dozen human studies, not exhaustive of what is found in the literature. Each study found circulating chemerin to be in the µg/l range. Children and normal humans were at the low 100 µg/l range. Two points can be made from this figure. First, humans of different ethnicities are represented. Notably, Chinese populations presented with among the lowest levels of circulating chemerin protein in what are considered clinically healthy adults (Figure 5). Second, the lowest level of circulating chemerin protein in tissues, as well as circulating (plasma) levels of chemerin in tissues, as well as circulating (plasma) levels of chemerin protein, were abolished compared with chemerin mRNA and protein expression was higher in the arteries and PVAT of the high fat vs. control group. Similarly, circulating chemerin was elevated in a rat model of preeclampsia. In another study, renal chemerin was elevated in a diabetic model, and Chemerin1 was upregulated in renal T cells in casein fed progeny of the Dahl S rat. This latter study used 2-(α-naphthoyl)ethyltrimethylammonium iodide as a Chemerin1 antagonist. Antagonism of Chemerin1 attenuated the hypertension of the Dahl S rat fed high salt, as well as renal damage. These studies are significant in that they support the activation of a chemerin receptor as mediating the disease.

In the rat, as in the human, the liver and adipose tissue are likely the greatest overall contributors to the body load of chemerin (Figure 1). Our group has used the above described ASOs in the rat that cause the degradation of chemerin (pre)mRNA to reduce chemerin protein levels. The ASO against chemerin has been validated. In rats given this ASO, chemerin mRNA expression and chemerin protein in tissues, as well as circulating (plasma) levels of chemerin protein, were abolished compared with chemerin mRNA and protein expression in the tissues and plasma from rats given a control, scrambled ASO. In normal male Sprague-Dawley rats, chemerin ASO treatment reduced mean arterial blood pressure by ~7 mm Hg. These data, combined with others discussed below, have been redrawn from in Figure 6. Similarly, the GalNAC ASO (liver-specific) against chemerin abolished liver chemerin mRNA, chemerin protein and reduced circulating chemerin levels to near zero, as determined by Western analysis. However, this same ASO was unable to reduce blood pressure. This suggests that while hepatic contributions dominate circulating plasma chemerin, liver chemerin is not involved in blood pressure determination.

The chemerin protein important to blood pressure regulation must be from other sources. We argue that adipose tissue is this source. In fact, the chemerin ASO could dramatically reduce the elevated blood pressure of the high fat but not high salt fed Dahl S rat, where the Dahl S is a recognized genetic model of hypertension. In the high fat Dahl S rat, the GalNAC ASO did not reduce the blood pressure of the high fat rat but almost abolished circulating chemerin levels (Figure 6).

These findings argue that it is not circulating but rather local chemerin that is most biologically relevant
to blood pressure. Figure 7 depicts a working hypothesis of our investigation of fat (primarily adipocytes) as a source of biologically relevant chemerin for blood pressure regulation. PVAT could be particularly important because it contains chemerin that could be secreted to affect both sympathetic nerve and vessel (endothelium, smooth muscle) function. It is also possible that PVAT fat produces particular isoforms of chemerin that are more effective than others in eliciting a biological response. If the human situation is similar, then measures of circulating plasma must be questioned as to their meaningfulness. Admittedly, we know of no way that would allow discrimination between PVAT and other adipose depots as sources of chemerin.

However, these data do not invalidate or diminish the substantial human data correlating blood pressure with circulating levels of chemerin. While local chemerin from the PVAT is likely facilitating the molecular effects leading to the changes in blood pressure, chemerin in the serum is likely secondary to these changes and still a good diagnostic indicator of what is happening on the local level.

WHAT WE NEED TO LEARN ABOUT CHEMERIN AND HYPERTENSION

We share ideas that would move the chemerin field forward, significantly past its strong but largely epidemiological support.

• We need more information as to the direct effects of chemerin in the heart, kidney, brain and adrenal. Specifically, we need to learn much more about the basic physiological functions of chemerin, what receptors chemerin utilizes to carry out these functions, and how this system changes in hypertensive disease. Additionally, we need to understand how much of chemerin receptor activation is from systemic (endocrine) vs. local (paracrine) prochemerin processing and metabolite distribution.

• We need tools that can selectively activate and inhibit chemerin1, chemerin2, and CCRL2. Possession of receptor subtype tools would help in determining more specific functions of chemerin at the tissue and whole-body level.

• We need to understand how important biased actions of chemerin receptors are to biological functions. We introduced the idea that chemerin’s action can be in opposition, an example being that chemerin is described as both inflammatory and inflammatory. Is this because different isoforms stimulate a different collective cadre of receptors (referred above)? Is this because the location of the receptor changes its actions? In this context, understanding whether the cellular machinery available to a chemerin receptor can change the biological outcome is important. Are there cell types, for example, in which chemerin and its isoforms act through receptors in a biased fashion, but others in which biased signaling is not possible?
We should be careful about interpretation of plasma concentration of chemerin in the human. This would require having assays that could discriminate between prochemerin and chemerin metabolites.

We need to determine how adipose tissue specifically contributes to functional chemerin. Adipocyte specific targeting of chemerin is currently a work in progress. There is much interest in being able to reduce adipocyte contributions, in general, but this field has been stymied by technical difficulties.

We need to understand the regulation of prochemerin processing into its myriad of active chemerin metabolites. Which proteases are essential vs. redundant? What is the tissue-dependency?

We need to identify whether there is a genetic association of Loss-of-Function or Gain-of-Function variants in chemerin signaling associated with disease. Work that has found an association of increased plasma chemerin and disease are intriguing but are not nearly as powerful of identifying whether genetic variants in chemerin or the chemerin receptors are associated with improved health or disease.

**Figure 6.** Effect of ASOs on mean arterial blood pressure (MAP) and plasma chemerin protein expression in the male Sprague-Dawley (left) and high salt (HS) or high fat (HF) Dahl S male rat. Whole-body ASO knocked down chemerin in all tissues, while the liver-specific ASO knocked down chemerin largely in the liver. Dahl S rats were either on a control, high fat (60% fat), or high salt (4% salt) diet. Data are adapted from refs. 110, 111. Bars represent means ± SEM for number of animals indicated by N. Abbreviation: ASO, antisense oligonucleotide.

**Figure 7.** Working hypothesis of the local actions of chemerin in the vasculature as facilitated by the perivascular adipose tissue (PVAT) as a source of chemerin that could activate chemerin 1 receptors on the sympathetic nerve (yellow) or smooth muscle cell to stimulate vascular contraction.
• We need to investigate whether therapeutics that modulate chemerin levels and/or chemerin receptor signaling have utility in treatment of cardiometabolic and/or inflammatory diseases.

FUNDING
American Heart Association Transformative grant 19TPA34850014 (SWW) and National Institutes of Health grant F31 HL 143937 (DJF).

DISCLOSURE
The authors declared no conflict of interest.

REFERENCES
1. Wittamer V, Franssen JD, Vulcano M, Mirjolet JE, Le Poul E, Mignotte I, Brézillon S, Tyldesley R, Blanpain C, Dethieux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198:977–985.
2. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol 2005; 175:487–493.
3. Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev 2011; 22:331–338 (doi:10.1016/j.cytogfr.2011.11.004).
4. Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol 2010; 185:3728–3739.
5. Iannone F, Lapadula G. Chemerin/ChemR23 pathway: a system beyond chemokines. Arthritis Res Ther 2011; 13:104.
6. Schipper HS, Prakken B, Kalkhoven E, Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol Metab 2012; 23:407–415.
7. Zabel BA, Allen SJ, Kulig P, Allen JA, Handel TM, Lee PP, Butcher EC. Leukemia. J Biol Chem 2003; 280:34661–34666.
8. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Morgan PJ. A neuroendocrine role for chemerin in hypothalamic remodelling and photoperiodic control of energy balance. Sci Rep 2016; 6:26830.
9. Mattern A, Zellmann T, Beck-Sickinger AG. Processing, signaling, and physiological function of chemerin. IUBMB Life 2014; 66:19–26.
10. Ge X, Yamaguchi Y, Zhao L, Bury L, Gresele P, Berube C, Leung LL, Morser J. Prochemerin cleavage by factor Xla links coagulation and inflammation. Blood 2018; 131:353–364.
11. Zhao L, Yamaguchi Y, Sharif S, Du XY, Song H, Lee DM, Recht LD, Robinson WH, Morser J, Leung LL. Chemerin158K protein is the dominant chemerin isoform in synovial and cerebrospinal fluids but not in plasma. J Biol Chem 2011; 286:39520–39527.
12. Zhao L, Yamaguchi Y, Ge X, Robinson WH, Morser J, Leung LLK. Chemerin 156G generated by chymase cleavage of prochemerin, is elevated in joint fluids of arthritis patients. Arthritis Res Ther 2018; 20:152.
13. Zhao L, Yamaguchi Y, Shen WJ, Morser J, Leung LLK. Dynamic and tissue-specific proteolytic processing of chemerin in obese mice. PLoS One 2018; 13:e0202780.
14. Du XY, Leung LL. Proteolytic regulatory mechanism of chemerin bioactivity. Acta Biochim Biophys Sin (Shanghai) 2009; 41:973–979.
15. Du XY, Zabel BA, Myles T, Allen SJ, Handel TM, Lee PP, Butcher EC. Leukemia. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem 2009; 284:751–758.
16. Guillabert A, Wittamer V, Bondue B, Godot V, Imbault V, Parmentier M, Communi D. Role of neutrophil protease 3 and mast cell chemorecognition in chemerin proteolytic regulation. J Leukoc Biol 2008; 84:1530–1538.
17. John H, Hierer J, Haas O, Forssmann WG. Quantification of angiogenesis- converting-enzyme-mediated degradation of human chemerin 145–154 in plasma by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Anal Biochem 2007; 362:117–125.
18. Parlee SD, McNeil JO, Muruganandan S, Sinal CJ, Goralski BA, Kelastase and tryptase govern TNFa-mediated production of active chemerin by adipocytes. PLoS One 2012; 7:e11072.
19. Chang SS, Eisenberg D, Zhao L, Adams C, Leib R, Morser J, Leung L. Chemerin activation in human obesity. Obesity (Silver Spring) 2016; 24:1522–1529.
20. Laranjeira S, Regan-Komito D, Ibqal AJ, Greaves DR, Payne SJ, Orlowski P. A model for the optimization of anti-inflammatory treatment with chemerin. Interface Focus 2018; 8:20170007.
21. Pohl R, Rein-Fischboeck L, Meier BM, Eisinger K, Krautbauer S, Buechler C, Resolvin E1 and chemerin C15 peptide do not improve rodent non-alcoholic steatohepatitis. Exp Mol Pathol 2015; 98:295–299.
22. Buechler C, Feder S, Habert EM, Aslanidis. Chemerin isoforms and activity in obesity. Int J Mol Sci 2019; 20:1118.
23. Huang H, Hu L, Lin J, Zhu X, Cui W, Xu W. Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats. Int J Clin Exp Pathol 2015; 8:11470–11474.
24. Yu QX, Zhang H, Liu SL, Bai MM, Mu JW, Zhang HJ. Effect of Irbesartan on chemerin in the renal tissues of diabetic rats. Kidney Blood Press Res 2015; 40:467–477.
25. Kennedy AJ, Davenport AP. International union of basic and clinical pharmacology CIII: chemerin receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) nomenclature, pharmacology, and function. Pharmacol Rev 2018; 70:174–196.
26. Monnier J, Lewén S, O’Hara E, Huang K, Tu H, Butcher EC, Zabel BA. Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells. J Immunol 2012; 189:956–967.
27. Wittamer V, Grégoire F, Bobberecht P, Vassart G, Communi D, Parmentier M. The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem 2004; 279:9956–9962.
28. Graham KL, Zhang J, Lewen S, Burke TM, Dang T, Zoulova M, Sobel RA, Butcher EG, Zabel BA. A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease. PLoS One 2014; 9:e112925.
29. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin Investig Drugs 2008; 17:969–972.
30. Huang Y. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids 2017; 6:116–132.
31. Watts SW, Dorrance AM, Penfold ME, Rourke JL, Sinal CJ, Seitz B, Sullivan TJ, Charvat TT, Thompson JM, Burnett R, Fink GD. Chemerin
connects fat to arterial contraction. *Arterioscler Thromb Vasc Biol* 2013; 33:1320–1328.

39. Darios ES, Winner BM, Charvat T, Kraskinska A, Punna S, Watts SW. The adipokine chemerin amplifies electrical field-stimulated contraction in the isolated rat superior mesenteric artery. *Am J Physiol Heart Circ Physiol* 2016; 311:H498–H507.

40. Ferland DJ, Darios ES, Neubig RR, Sjögren B, Truong N, Torres R, Dexeheimer TS, Thompson JM, Watts SW. Chemerin-induced arterial contraction is Gi- and calcium-dependent. *Vascul Pharmacol* 2017; 88:30–41.

41. Hanthazi A, Jespers P, vegh G, Degroot G-N, Springael J-Y, Lybaert P, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, Tegel H, Mulder J, Hamsten M. Chemerin and Hypertension. *Am J Heart Assoc* 2016; 5:e004421.

42. Kostopoulos CG, Spioglio SG, Varakis JN, Apostolakis E, Papadaki HHC. Chemerin and CMKLRI expression in human arteries and periadventitial fat: a possible role for local chemerin in atherosclerosis? *BMC Cardiovasc Disord* 2014; 14:56.

43. Lobato NS, Neves KB, Filgueira FP, Lopes RA, Rios FF, Anagnostopoulou A, Lobato NS, Neves KB, Lopes RA, Rios FF, Fortes ZB, Carvalho MH, Webb RC, Udenfriend S, Webb RC, Udenfriend S. Chemerin connects fat to arterial contraction. *Arterioscler Thromb Vasc Biol* 2013; 33:1320–1328.

44. Neves KB, Lobato NS, Lopes RA, Filgueira FP, Zanotto CZ, Oliveira AM. Chemerin regulates crosstalk between adipocytes and vascular cells through Nox. *Hypertension* 2015; 66:57–66.

45. Neves KB, Lobato NS, Rios RA, Filgueira FP, Zanotto CZ, Oliveira AM, Tostes RC. Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity? *Clin Sci (Lond)* 2014; 127:111–122.

46. De Henau O, Degroot G-N, Imbault V, Robert V, De Poorter C, Robert V, De Poorter C. Chemerin regulates crosstalk between adipocytes and vascular cells through Nox. *Hypertension* 2015; 66:57–66.

47. Kunimoto H, Kazama K, Takai M, Oda M, Okada M, Yamawaki H. Chemerin stimulates aortic smooth muscle cell proliferation and migration via chemokine-like receptor 1 (CMKLRI), not G-protein coupled receptor 1 (GPR1), in human and rat vasculature. *J Am Heart Assoc* 2016; 5:e004421.
75. Huang J, Zhang J, Lei T, Chen X, Zhang Y, Zhou L, Yu A, Chen Z, Zhou R, Yang Z. Cloning of porcine chemerin, ChemR23 and GPR1 and their involvement in regulation of lipogenesis. *BMB Rep* 2010; 43:491–498.

76. Lin S, Teng J, Liu J, Sun F, Yuan D, Chang J. Association of chemerin and vascular endothelial growth factor (VEGF) with diabetic nephropathy. *Med Sci Monit* 2016; 22:3209–3214.

77. Mocke A, Hilerus KF, Cordasic N, Wachtveitl R, Menendez-Castro C, Woelfle J, Hartner A, Fahlbusch FB. Renal chemerin expression is induced in models of hypertensive nephropathy and glomerulosclerosis and correlates with markers of inflammation and fibrosis. *Int J Mol Sci* 2019; 20:6240 (doi:10.3390/ijms20246240).

78. Mariani F, Roncucci L. Chemerin/chemR23 axis in inflammation onset and resolution. *Inflamm Res* 2015; 64:35–95.

79. Della Chiesa M, Sivori S, Castriconi R, Marcenaro E, Moretta A. Pathogen-induced private conversations between natural killer and dendritic cells. *Trends Microbiol* 2005; 13:128–136.

80. Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid dendritic cells from myeloid dendritic cells in human blood. *J Immunol* 2005; 174:244–251.

81. Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the immune system in pathogenesis and resolution of dIabeteS in obese paTIeNts (The RESISTIN trial). *Cytokine* 2020; 127:154947.

82. Yin C, Chu H, Li H, Xiao Y. Plasma Sfrp5 and adiponectin levels in relation to non-alcoholic fatty liver disease. *Ferdal* et al. 2016; 31:924–931.

83. Lu B, Zhao M, Jiang W, Ma J, Yang C, Shao J, Gu P. Independent association of circulating level of chemerin with functional and early morphological vascular changes in newly diagnosed Type 2 diabetic patients. *Medicine (Baltimore)* 2015; 94:e1990.

84. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in Caucasian population—a pilot study. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2008; 152:217–221.